STOCK TITAN

[Form 4] Myomo Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Myomo, Inc. (MYO) – Form 4 insider transaction

Chief Medical Officer Harry Kovelman reported the automatic sale of 13,054 common shares on 30 June 2025 at $2.19 per share. The transaction is coded “F,” indicating the shares were withheld solely to cover income taxes arising from the vesting of restricted stock units on 28 June 2025. After the sale, Kovelman still beneficially owns 140,618 shares, held directly. No derivative securities were acquired or disposed of, and no additional transactions are disclosed.

The filing appears to be a routine tax-related share withholding rather than a discretionary market sale and does not materially change insider ownership levels.

Myomo, Inc. (MYO) – Transazione insider Form 4

Il Chief Medical Officer Harry Kovelman ha segnalato la vendita automatica di 13.054 azioni ordinarie il 30 giugno 2025 al prezzo di 2,19 $ per azione. La transazione è contrassegnata con il codice “F”, che indica che le azioni sono state trattenute esclusivamente per coprire le imposte sul reddito derivanti dalla maturazione delle unità di azioni ristrette il 28 giugno 2025. Dopo la vendita, Kovelman detiene ancora beneficiariamente 140.618 azioni, detenute direttamente. Non sono stati acquisiti o ceduti titoli derivati e non sono state divulgate ulteriori transazioni.

La comunicazione sembra essere una normale ritenuta fiscale sulle azioni piuttosto che una vendita discrezionale sul mercato e non modifica in modo significativo i livelli di proprietà degli insider.

Myomo, Inc. (MYO) – Transacción interna Formulario 4

El Director Médico Harry Kovelman reportó la venta automática de 13.054 acciones comunes el 30 de junio de 2025 a $2.19 por acción. La transacción está codificada como “F”, lo que indica que las acciones fueron retenidas únicamente para cubrir impuestos sobre la renta derivados de la adquisición de unidades restringidas de acciones el 28 de junio de 2025. Tras la venta, Kovelman aún posee beneficiosamente 140,618 acciones, mantenidas directamente. No se adquirieron ni vendieron valores derivados, y no se revelaron transacciones adicionales.

La presentación parece ser una retención rutinaria de acciones relacionada con impuestos en lugar de una venta discrecional en el mercado y no cambia materialmente los niveles de propiedad interna.

Myomo, Inc. (MYO) – Form 4 내부자 거래

최고 의료 책임자 해리 코벨먼(Harry Kovelman)은 2025년 6월 30일에 보통주 13,054주를 주당 $2.19에 자동으로 매도했다고 보고했습니다. 거래 코드는 “F”로, 이는 2025년 6월 28일 제한 주식 단위가 확정됨에 따라 발생한 소득세를 충당하기 위해 주식을 보유한 것임을 나타냅니다. 매도 후 코벨먼은 직접 보유한 140,618주를 여전히 실질적으로 소유하고 있습니다. 파생 증권의 취득 또는 처분은 없었으며 추가 거래도 공개되지 않았습니다.

이번 신고는 임의의 시장 매도가 아니라 세금 관련 주식 원천징수로 보이며 내부자 소유 지분에 실질적인 변동을 주지 않습니다.

Myomo, Inc. (MYO) – Transaction d'initié Formulaire 4

Le directeur médical Harry Kovelman a déclaré la vente automatique de 13 054 actions ordinaires le 30 juin 2025 au prix de 2,19 $ par action. La transaction est codée « F », indiquant que les actions ont été retenues uniquement pour couvrir les impôts sur le revenu liés à l'acquisition des unités d'actions restreintes le 28 juin 2025. Après la vente, Kovelman détient toujours bénéficiairement 140 618 actions, détenues directement. Aucun titre dérivé n'a été acquis ou cédé, et aucune transaction supplémentaire n'est divulguée.

Le dépôt semble être une retenue d'actions liée à des obligations fiscales, plutôt qu'une vente discrétionnaire sur le marché, et ne modifie pas de manière significative les niveaux de détention des initiés.

Myomo, Inc. (MYO) – Insider-Transaktion Form 4

Chief Medical Officer Harry Kovelman meldete den automatischen Verkauf von 13.054 Stammaktien am 30. Juni 2025 zu je 2,19 $. Die Transaktion ist mit „F“ codiert, was bedeutet, dass die Aktien ausschließlich einbehalten wurden, um die Einkommensteuern zu decken, die durch die Ausübung von Restricted Stock Units am 28. Juni 2025 entstanden sind. Nach dem Verkauf besitzt Kovelman weiterhin wirtschaftlich 140.618 Aktien, die direkt gehalten werden. Es wurden keine Derivate erworben oder veräußert, und es werden keine weiteren Transaktionen offengelegt.

Die Meldung scheint eine routinemäßige steuerbedingte Aktieneinbehaltung zu sein und keine freiwillige Marktveräußerung, die die Insider-Besitzverhältnisse wesentlich verändert.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine tax-withholding sale; negligible impact on insider alignment or valuation.

The Form 4 records a mandatory “F” transaction, whereby Harry Kovelman surrendered 13,054 shares (~$28 k) to satisfy tax obligations from RSU vesting. The insider retains 140,618 shares, so his economic exposure remains largely intact. Because the sale is non-discretionary and immaterial to Myomo’s float or governance profile, I view the disclosure as neutral for investors and not market-moving. No new options, warrants, or other derivatives were granted or exercised.

Myomo, Inc. (MYO) – Transazione insider Form 4

Il Chief Medical Officer Harry Kovelman ha segnalato la vendita automatica di 13.054 azioni ordinarie il 30 giugno 2025 al prezzo di 2,19 $ per azione. La transazione è contrassegnata con il codice “F”, che indica che le azioni sono state trattenute esclusivamente per coprire le imposte sul reddito derivanti dalla maturazione delle unità di azioni ristrette il 28 giugno 2025. Dopo la vendita, Kovelman detiene ancora beneficiariamente 140.618 azioni, detenute direttamente. Non sono stati acquisiti o ceduti titoli derivati e non sono state divulgate ulteriori transazioni.

La comunicazione sembra essere una normale ritenuta fiscale sulle azioni piuttosto che una vendita discrezionale sul mercato e non modifica in modo significativo i livelli di proprietà degli insider.

Myomo, Inc. (MYO) – Transacción interna Formulario 4

El Director Médico Harry Kovelman reportó la venta automática de 13.054 acciones comunes el 30 de junio de 2025 a $2.19 por acción. La transacción está codificada como “F”, lo que indica que las acciones fueron retenidas únicamente para cubrir impuestos sobre la renta derivados de la adquisición de unidades restringidas de acciones el 28 de junio de 2025. Tras la venta, Kovelman aún posee beneficiosamente 140,618 acciones, mantenidas directamente. No se adquirieron ni vendieron valores derivados, y no se revelaron transacciones adicionales.

La presentación parece ser una retención rutinaria de acciones relacionada con impuestos en lugar de una venta discrecional en el mercado y no cambia materialmente los niveles de propiedad interna.

Myomo, Inc. (MYO) – Form 4 내부자 거래

최고 의료 책임자 해리 코벨먼(Harry Kovelman)은 2025년 6월 30일에 보통주 13,054주를 주당 $2.19에 자동으로 매도했다고 보고했습니다. 거래 코드는 “F”로, 이는 2025년 6월 28일 제한 주식 단위가 확정됨에 따라 발생한 소득세를 충당하기 위해 주식을 보유한 것임을 나타냅니다. 매도 후 코벨먼은 직접 보유한 140,618주를 여전히 실질적으로 소유하고 있습니다. 파생 증권의 취득 또는 처분은 없었으며 추가 거래도 공개되지 않았습니다.

이번 신고는 임의의 시장 매도가 아니라 세금 관련 주식 원천징수로 보이며 내부자 소유 지분에 실질적인 변동을 주지 않습니다.

Myomo, Inc. (MYO) – Transaction d'initié Formulaire 4

Le directeur médical Harry Kovelman a déclaré la vente automatique de 13 054 actions ordinaires le 30 juin 2025 au prix de 2,19 $ par action. La transaction est codée « F », indiquant que les actions ont été retenues uniquement pour couvrir les impôts sur le revenu liés à l'acquisition des unités d'actions restreintes le 28 juin 2025. Après la vente, Kovelman détient toujours bénéficiairement 140 618 actions, détenues directement. Aucun titre dérivé n'a été acquis ou cédé, et aucune transaction supplémentaire n'est divulguée.

Le dépôt semble être une retenue d'actions liée à des obligations fiscales, plutôt qu'une vente discrétionnaire sur le marché, et ne modifie pas de manière significative les niveaux de détention des initiés.

Myomo, Inc. (MYO) – Insider-Transaktion Form 4

Chief Medical Officer Harry Kovelman meldete den automatischen Verkauf von 13.054 Stammaktien am 30. Juni 2025 zu je 2,19 $. Die Transaktion ist mit „F“ codiert, was bedeutet, dass die Aktien ausschließlich einbehalten wurden, um die Einkommensteuern zu decken, die durch die Ausübung von Restricted Stock Units am 28. Juni 2025 entstanden sind. Nach dem Verkauf besitzt Kovelman weiterhin wirtschaftlich 140.618 Aktien, die direkt gehalten werden. Es wurden keine Derivate erworben oder veräußert, und es werden keine weiteren Transaktionen offengelegt.

Die Meldung scheint eine routinemäßige steuerbedingte Aktieneinbehaltung zu sein und keine freiwillige Marktveräußerung, die die Insider-Besitzverhältnisse wesentlich verändert.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kovelman Harry

(Last) (First) (Middle)
C/O MYOMO, INC.
45 BLUE SKY DR., SUITE 101

(Street)
BURLINGTON MA 01803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MYOMO, INC. [ MYO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 F 13,054(1) D $2.19 140,618 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents sale of shares on June 30, 2025, solely to cover income taxes on the vesting of restricted stock units on June 28, 2025, pursuant to an irrevocable election made by the Reporting Party on May 12, 2025.
/s/ David A. Henry, Attorney-in-Fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Myomo (MYO) shares did the Chief Medical Officer sell on 30 June 2025?

He sold 13,054 shares of common stock at $2.19 each.

Why were the shares sold according to the Form 4 filing?

The shares were sold solely to cover income taxes related to the vesting of restricted stock units on 28 June 2025.

What is Harry Kovelman’s remaining ownership in Myomo after the transaction?

He continues to beneficially own 140,618 shares of Myomo common stock.

What does transaction code "F" represent in this Form 4?

Code "F" indicates a sale of shares to satisfy tax withholding obligations.

Did the filing report any option exercises or other derivative activity?

No. Table II shows no derivative securities were acquired or disposed of.

When did the restricted stock units underlying the tax withholding vest?

The RSUs vested on 28 June 2025.
Myomo

NYSE:MYO

MYO Rankings

MYO Latest News

MYO Latest SEC Filings

MYO Stock Data

73.40M
31.60M
5.14%
59.2%
2.28%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
BOSTON